Fig. 2

Overview of sequencing workflows. Numbers of samples sequenced at each stage indicated. Due to sample availability, project stage, and local infrastructure, we used different subsets of samples to validate each method. In the clinical sample set from South Africa, if residual extract was available after capture, two further aliquots were taken forward for HEP-TILE enrichment and sequencing on Nanopore and Illumina. Created in BioRender. Lumley, S. (2024) BioRender.com/k41p399.